Mohammad Javad Emami Kazemabad

Mohammad Javad Emami Kazemabad

Auto-generated profile, based on publicly available information

Mohammad Javad Emami Kazemabad

Student Research Committee, School of Medicine, Qom University of Medical Sciences, Qom, Iran

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Current Cancer Therapy Reviews
Verified
Journal Article
Closed access
PDF file
MKMohammad Javad Emami Kazemabad
Mohammad Javad Emami Kazemabad
PDParisa Alsadat Dadkhah
Parisa Alsadat Dadkhah
HAHanieh Amani
Hanieh Amani
STSara Asgari Toni
Sara Asgari Toni
MAMohammad Yasin Izadi Alamshiry
Mohammad Yasin Izadi Alamshiry
SKSamira Khani
Samira Khani
In contemporary medicine, cancers are recognized as significant concerns warranting attention. Over time, scientific advancements have assisted physicians worldwide in exploring novel approaches. Among these potential solutions are calcium channel blockers (CCBs), which hold considerable importance and find extensive application across various medical conditions. CCBs, classified as dihydropyridines and non-dihydropyridines, have been widely utilized in the management of diverse cancer types. Given the diverse facets of dihydropyridine CCBs, our objective was to comprehensively gather and summarize pertinent data regarding the impact of this medication class on different cancer types.